Biotechnology News and Research RSS Feed - Biotechnology News and Research

SkylineDx’s MMprofiler test helps predict prognosis of patients with multiple myeloma

SkylineDx’s MMprofiler test helps predict prognosis of patients with multiple myeloma

SkylineDx, an innovative biotechnology company specialising in the development and commercialization of genetic tests, is today launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. [More]
Domainex’s new integrated bioassay service platform accelerates progression of drug discovery projects

Domainex’s new integrated bioassay service platform accelerates progression of drug discovery projects

Domainex Ltd, a private drug discovery service company, today announces that it is launching an integrated bioassay service platform, BioassayBuilder. [More]
ExeGi Pharma granted product license to sell Visbiome formulation in Canada

ExeGi Pharma granted product license to sell Visbiome formulation in Canada

ExeGi Pharma, a company focused on developing and commercializing live biotherapeutics and probiotic treatments, announced today that it has been granted a product license by the Health Canada Natural and Non-prescription Health Products Directorate (NNHPD) to sell Visbiome in Canada. [More]
Discovery Laboratories gets notice of noncompliance from Nasdaq Stock Market related to minimum bid price

Discovery Laboratories gets notice of noncompliance from Nasdaq Stock Market related to minimum bid price

Discovery Laboratories, Inc. announced today that, on June 29, 2015, the Company received a letter from The Nasdaq Stock Market indicating that, because the Company's common stock has not maintained a minimum closing bid price of $1.00 per share over the previous 30 consecutive business days, the Company is no longer in compliance with Nasdaq's Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). [More]
Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

Nuclea Biotechnologies Inc. announced today that it is partnering with Aelan Cell Technologies Inc. (San Francisco, California) for the development, validation and commercialization of novel biomarker tests and companion diagnostics using human STEM cells as models. [More]
Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration. [More]
CTI Biotechnology implements Xybion's Pristima 7 Preclinical Suite

CTI Biotechnology implements Xybion's Pristima 7 Preclinical Suite

Xybion Corporation, leading provider of preclinical R&D solutions announced today that CTI Biotechnology in Suzhou, China has implemented Xybion's Pristima 7 Preclinical Suite. Pristima® was selected after an exhaustive evaluation of top selling preclinical software systems on the market. [More]
Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. [More]

BioClinica expands presence in Europe

BioClinica, Inc., the world's leading specialty clinical trial service provider, announced today the opening of new and expanded offices in London and Munich to better serve its growing client base in Europe. [More]
Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

The Government of the Republic of Equatorial Guinea announced an agreement with industry partners, Marathon Oil Corporation, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 until 2018. [More]
Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

The amphetamine-based drug Evekeo, given once or twice daily to children 6-12 years of age, is effective in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting, according to the results of a new study published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease. [More]
Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia. [More]
Veracyte named to Bay Area News Group's Top Workplaces list for second consecutive year

Veracyte named to Bay Area News Group's Top Workplaces list for second consecutive year

Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has been named to the Bay Area News Group's prestigious Top Workplaces list for the second year in a row. The news group selects Top Workplace winners based solely on an annual survey of Bay Area-company employees. [More]
Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study. [More]
Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. [More]

ASEAN poised to be the next economic powerhouse of Asia

With a 600 million plus population and pharmaceutical market demand of USD21.3 billion in 2014, Association of Southeast Asian Nations (ASEAN) is poised to be the next economic powerhouse of Asia, through efforts such as the ASEAN Harmonization and Bioeconomy Transformation Programme. [More]

Bristol-Myers Squibb to establish R&D center in Cambridge Kendall Square innovation cluster

Alexandria Real Estate Equities, Inc., the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation clusters, announced today that Bristol-Myers Squibb, a global biopharmaceutical company, will establish a state-of-the-art research and development center at the Alexandria Center at Kendall Square (ACKS) in the heart of the Cambridge Kendall Square innovation cluster. [More]
BIOCITECH, Seine-Saint-Denis CCI announce winners of first BIOCITECH Funding Day

BIOCITECH, Seine-Saint-Denis CCI announce winners of first BIOCITECH Funding Day

BIOCITECH, the city complex for healthcare and biotechnology businesses and the Seine-Saint-Denis Chamber of Commerce and Industry (CCI), today announce the three winners of the first BIOCITECH Funding Day. [More]
Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journal Cannabis and Cannabinoid Research, strongly supports President Obama's statement that "...carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue," when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs. [More]
Advertisement
Advertisement